Simulations Plus (SLP) Stock Price, News & Analysis

Company Overview

Simulations Plus, Inc. develops software and provides services that support pharmaceutical research, drug development and regulatory decision-making. Its technologies help scientists model how drug compounds behave in the body, assess formulation and delivery characteristics, and evaluate potential safety and efficacy outcomes.

The company’s software portfolio includes GastroPlus, a platform for physiologically based pharmacokinetic and pharmacodynamic modeling; ADMET Predictor, which forecasts absorption, distribution, metabolism, excretion and toxicity properties; and DDDPlus, which simulates drug dissolution and dosage-form performance. Simulations Plus also offers tools for membrane permeability, medicinal chemistry and related drug-development applications.

In addition to its software products, Simulations Plus provides consulting and contract research services involving pharmacometrics, pharmacokinetics, pharmacodynamics, clinical trial simulation and model-informed drug development. Founded in 1996, the company is headquartered in Lancaster, California, and serves pharmaceutical and biotechnology companies, regulatory agencies, academic institutions and other organizations worldwide.

Key Stats

• Today's Range: $18.50 to $18.50
• 50-Day Range: $18.31 to $18.50
• 52-Week Range: $11.09 to $21.01
• Volume: N/A
• Average Volume: 253,980 shs
• Market Capitalization: $374.16 million
• P/E Ratio: 46.25
• Dividend Yield: N/A
• Price Target: $17.25
• Consensus Rating: Reduce

Simulations Plus Stock Analysis - MarketRank™

Simulations Plus scored higher than 24% of companies evaluated by MarketBeat, and ranked 790th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Reduce

Consensus Rating

Simulations Plus has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no strong buy ratings, no buy ratings, 7 hold ratings, and 1 sell rating.

Downside Risk

Simulations Plus has a consensus price target of $17.25, representing about 6.8% downside from its current price of $18.50.

Amount of Analyst Coverage

Simulations Plus has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Simulations Plus is 46.25, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.05.

Price to Earnings Ratio vs. Sector

The P/E ratio of Simulations Plus is 46.25, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.02.

Price to Book Value per Share Ratio

Simulations Plus has a P/B Ratio of 2.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.60% of the float of Simulations Plus has been sold short.

Short Interest Ratio / Days to Cover

Simulations Plus has a short interest ratio ("days to cover") of 15.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Simulations Plus has recently decreased by 0.47%, indicating that investor sentiment is improving.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Simulations Plus does not currently pay a dividend.

Dividend Growth

Simulations Plus does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Simulations Plus is 60.00%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.45

News Sentiment

Simulations Plus has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Simulations Plus this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for SLP on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

2 people have added Simulations Plus to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Simulations Plus insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.10% of the stock of Simulations Plus is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

78.08% of the stock of Simulations Plus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/09/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 8/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:SLP
• CIK: 1023459
• Web: www.simulations-plus.com
• Phone: (661) 723-7723
• Fax: 661-723-5524
• Employees: 213
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Simulations Plus: $17.25
• High Price Target: $18.50
• Low Price Target: $16.00
• Potential Upside/Downside: -6.8%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.40
• Trailing P/E Ratio: 46.25
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$64.72 million
• Net Margins: 9.88%
• Pretax Margin: 15.30%
• Return on Equity: 13.50%
• Return on Assets: 12.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.54
• Quick Ratio: 5.54

Sales & Book Value

• Annual Sales: $82.06 million
• Price / Sales: 4.56
• Cash Flow: $1.43 per share
• Price / Cash Flow: 12.93
• Book Value: $6.20 per share
• Price / Book: 2.98

Miscellaneous

• Outstanding Shares: 20,225,000
• Free Float: 16,362,000
• Market Cap: $374.16 million
• Optionable: Optionable
• Beta: 1.31